Displaying drugs 451 - 475 of 554 in total
Adecatumumab
Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.
Investigational
Matched Description: … EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor …
Phosphorus P-32
Phosphorus P-32 is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.
Experimental
Matched Description: … free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor …
SVV-001
SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features. SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that...
Investigational
IDD-3
IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
Investigational
Matched Description: … It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. …
Lucanthone
One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.
Investigational
ING-1
ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractive target for immunotherapy.
Investigational
Eniluracil
Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for a variety...
Investigational
Gabexate
Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220]
Investigational
Biricodar
The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
Investigational
Tanespimycin
Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.
Investigational
2-Methoxyestradiol
2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis). It has undergone Phase 1 clinical trials against breast cancers and preclinical studies suggest that 2ME2 could also be effective against inflammatory diseases such as rheumatoid arthritis.
Investigational
Dovitinib
Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I...
Investigational
Matched Description: … orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor …
Polyvalent antigen-KLH conjugate vaccine
Polyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant keyhole limpet hemocyanin (KLH). It is under investigation in clinical trial NCT01223235 (Polyvalent Vaccine-klh Conjugate + Opt-821 Given in Combination With Bevacizumab).
Investigational
Matched Description: … Polyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of the five tumor-associated …
NV1020
NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
Investigational
Bavituximab
Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.
Investigational
Varlitinib
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
Investigational
Matched Description: … Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and …
Trabedersen
Investigational
KOS-1584
KOS-1584 is a second-generation epothilone. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors. KOS-1584 is a second-generation compound with increased potency, favorable tissue distribution, and ease of formulation.
Investigational
SN-38
7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan DB00762, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negative...
Investigational
GMX1777
GMX1777 is a water-soluble prodrug of the cyanoguanidine compound GMX1778 with potential antineoplastic activity. In vivo, apoptosis inducer GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a carbonate ester bond. Although the exact mechanism of action has yet to be fully elucidated, GMX1778 appears to antagonize nuclear factor-kappa...
Investigational
Matched Description: … GMX1778 appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor …
Olmutinib
Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals . Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in...
Investigational
OSI-7836
OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine. It is also more active than ara-C (another clinically used nucleoside...
Investigational
Matched Description: … The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine. …
OSI-930
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
Matched Description: … In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung …
DOTMP HO-166
DOTMP HO-166 is used in skeletal targeted radiotherapy (STR). SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in the bone marrow. It is an experimental therapy...
Investigational
Matched Description: … to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor …
Displaying drugs 451 - 475 of 554 in total